References
- Tutwiler GF, Rasmussen CR, Tuman RW, et al. Pharmacological profile of linogliride fumarate. Diabetes 1984;33:24A.
- Levin PA, Jovanovic L, Chalew SA, et al. Linogliride fumarate, representing a new class of oral hypoglycemic agent for diabetes. Clin Pharmacol Ther 1987;42:498–503.
- Wu WN, Mutter MR. Biotransformation of linogliride, a hypoglycemic agent in laboratory animals and humans. J Pharm Biomed Anal 1995;13:857–67.
- McNeil Pharmaceutical Inc. Unpublished data. Spring House: s.n.
- Chrzanowski FA. Preformulation considerations for controlled release dosage forms. Part I: selecting candidates. AAPS PharmSciTech 2008;9:635–8.
- Welling PG. Oral controlled drug administration: pharmacokinetic considerationss. Drug Dev Ind Pharm 1983;9:1185–225.
- Madan PL. Sustained-release drug delivery systems: part I. An overview. Pharm Manuf 1985;2:23–7.
- Wu WN, Ng KT, Mutter MS. Metabolism of linogliride (Lg) in the rat, dog and man. Fed Pro, Fed Am Soc Exp Biol: (US) Conference 70. Annual Meeting of the Fed of Am Soc for Exp Biol, 13 Apr 1986; Vol. 45:3.
- Berge SM, Bighley LG, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977;66:1–19.
- Morozowich W, Chulski T, Hamlin WE, et al. Relationship between in vitro dissolution rates, solubilities and the LT50s in mice of some salts of benzphetamine and etryptamine. J Pharm Sci 1962;51:993–6.
- Benjamin EJ, Lin L-H. Preparation and in vitro evaluation of salts of antihypertensive agents to obtain slow release. Drug Dev Ind Pharm 1985;11:771–90.
- Gray AP, Robinson DS. Narcotic antagonists: insoluble salts and salt complexes of cyclazocine and naloxone. In: Harris EL, May EL, Smith JP, et al., eds. Advances in biochemical psychopharmacology. Vol. 8. s.l.: Raven Press; 1974:555–68.
- Thompson PE, Olszewski BJ, Elslanger EF, Worth DF. Laboratory studies on 4,6-diamino-1-(p-chlorophenyl)-1,2-dihydro-2,2-dimethyl-s-triazine pamoate as a repository antimalarial drug. Am J Trop Med Hyg 1963;12:481–93.
- Caldwell HC, Rednick AB, Scott GC, et al. Latentiation of dihydrostreptomycin by pamoate formation. J Pharm Sci 1970;59:1681–90.
- Cavallito CJ, Jewell R. Modification of rates of gastrointestinal absorption of drugs I. Amines. J Am Pharm Assoc Sci Ed 1958;47:165–8.
- Elving PJ, Markowitz JM, Rosenthal I. The preparation of buffer systems of constant ionic strength. Anal Chem 1956;28:1170.
- Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc 1897;19:930–4.
- Wagner JG. Rate of dissolution in vitro and in vivo Part V. Factors affecting rate of dissolution and interpretation of dissolution rate data from in vitro test of tablets and capsules. Drug Intell Clin Pharm 1970;4:132–7.
- Higuchi WI, Hamlin WE. Release of drug from a selfcoating surface. Benzphetamine pamoate pellet. J Pharm Sci 1963;52:575–9.
- Levy G, Procknal JA. Unusual dissolution behavior due to film formation. J Pharm Sci 1962;51:294.
- Serajuddin ATM, Jarowski CI. Effect of diffusion layer pH and solubility on the dissolution rate of pharmaceutical bases and their hydrochloride salts I: phenazopyridine. J Pharm Sci 1985;74:142–7.